Delcath Systems (NASDAQ:DCTH) Coverage Initiated by Analysts at started coverage on shares of Delcath Systems (NASDAQ:DCTHGet Rating) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Separately, Canaccord Genuity Group cut their price objective on shares of Delcath Systems from $24.00 to $20.00 and set a “buy” rating for the company in a report on Monday, April 11th.

NASDAQ DCTH opened at $4.70 on Friday. The firm has a market cap of $37.16 million, a P/E ratio of -1.29 and a beta of 0.53. The company has a quick ratio of 4.99, a current ratio of 5.23 and a debt-to-equity ratio of 1.26. The company’s 50 day moving average is $6.19 and its 200-day moving average is $7.53. Delcath Systems has a 12-month low of $4.30 and a 12-month high of $13.50.

Delcath Systems (NASDAQ:DCTHGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.12). Delcath Systems had a negative return on equity of 174.36% and a negative net margin of 721.72%. During the same quarter in the prior year, the company earned ($1.04) earnings per share. Equities analysts expect that Delcath Systems will post -3.08 EPS for the current year.

In other news, COO John Purpura purchased 5,000 shares of the business’s stock in a transaction on Monday, April 11th. The stock was purchased at an average cost of $6.59 per share, with a total value of $32,950.00. Following the acquisition, the chief operating officer now directly owns 23,721 shares in the company, valued at $156,321.39. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders purchased 14,100 shares of company stock valued at $91,520. 16.76% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in DCTH. Virtu Financial LLC bought a new position in Delcath Systems in the 4th quarter valued at $114,000. State Street Corp boosted its holdings in Delcath Systems by 70.3% in the 4th quarter. State Street Corp now owns 25,200 shares of the company’s stock valued at $195,000 after purchasing an additional 10,400 shares during the period. Susquehanna International Group LLP bought a new position in Delcath Systems in the 4th quarter valued at $209,000. Millennium Management LLC bought a new position in Delcath Systems in the 2nd quarter valued at $405,000. Finally, CI Investments Inc. bought a new position in Delcath Systems in the 1st quarter valued at $559,000. 21.93% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems (Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

See Also

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.